Elon Musk Excites Psychedelic Industry CEOs with This Tweet
This is one of the billionaire’s most explicit acknowledgments of the power of psychedelics for mental health applications.
This is one of the billionaire’s most explicit acknowledgments of the power of psychedelics for mental health applications.
Field Trip Health plans to split into two independent, publicly traded companies: Field Trip Health and Wellness and Reunion Neuroscience.
Psychiatrist, researcher, and CEO of Zylorion Health, Dr. Peter Silverstone, ranks psychedelic medicines based on their potential to revolutionize mental health treatment.
Here’s why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
PharmaTher evaluates safety, tolerability and efficacy of low-dose ketamine infusion for treatment of LID in Parkinson’s Disease patients.
This week in psychedelic business news: A psychedelics company folds; Ketamine Wellness Centers expand; Nova Mentis funds psilocybin studies.
We unpack five of the most important psychedelic studies conducted in recent years as psychedelics become mainstream medicine.
“Considering all our advocacy on this issue, this employee benefit is the next logical step,” says company president Michael Bronner.
This week in psychedelic business news: Core One cheapens psilocybin production; Field Trip eyes Oregon; Small Pharma advances DMT.
This week on the Psychedelic Spotlight podcast, we’re chatting with Dr. Erica Zelfand. She is a family doctor specializing in integrative and functional family medicine. She’s also a ketamine prescriber, facilitator of therapeutic experiences, and a medical writer and public speaker.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.